The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody.
Open accessAbstract
Recombinant human interleukin 1 receptor antagonist (IL-1ra) and 35F5, a neutralizing monoclonal antibody (mAb) to the type I mouse IL-1 receptor, were examined for their ability to bind to IL-1 receptors (IL-1Rs) on various types of mouse cells and to block immune and inflammatory responses to IL-1 in vitro and in mice. IL-1ra competed for binding of 125I-IL-1 alpha to type I IL-1R present on EL-4 thymoma cells, 3T3 fibroblasts, hepatocytes, and Chinese hamster ovary cells expressing recombinant mouse type I IL-1R. The IC50 values for IL-1ra binding (ranging from 2 to 4 ng/ml) were similar to those of IL-1 alpha. In contrast, IL-1ra bound with very low affinity (IC50 values ranging from 10 to 200 micrograms/ml) to cells expressing type II IL-1R, i.e., 70Z/3 pre-B cell line and polymorphonuclear leukocytes (PMN) derived from bone marrow and acute inflammatory exudates. The mAb 35F5 bound specifically to type I IL-1R; no inhibition of 125I-IL-1 alpha binding to cells having type II IL-1R was observed with very high concentrations of antibody. While neither IL-1ra nor 35F5 had intrinsic activity in bioassays using T helper D10.G4.1 cells and mouse thymocytes, both agents blocked the ability of IL-1 to stimulate proliferation of these cells. The effects of IL-1ra and 35F5 on acute inflammatory responses in mice were also evaluated. IL-1ra and 35F5 blocked the local accumulation of PMN after intraperitoneal injection of rIL-1 alpha. The response to IL-1 was inhibited when IL-1ra or 35F5 was administered simultaneously with or before administration of IL-1. IL-1ra and 35F5 also blocked PMN accumulation after intraperitoneal injection of lipopolysaccharide or proteose peptone, suggesting IL-1 is important in mediating responses to these agents. In addition, IL-1ra and 35F5 significantly blocked the ability of IL-1 to stimulate egress of PMN from bone marrow, to induce a transient neutrophilia, and to elevate serum levels of hepatic acute phase proteins, IL-6, and corticosterone. Thus, IL-1ra and 35F5 competitively inhibit the binding of IL-1 to the IL-1R on certain cell types. These two IL-1 receptor antagonists act to inhibit biological responses induced by IL-1 and other inflammatory agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor
Hannum, C. H., Wilcox, C. J., Arend, W. P., Joslin, F. G., Dripps, D. J., Heimdal, P. L., Armes, L. G., Sommer, A., Eisenberg, S. P., & Thompson, R. C. (1990) · Nature · doi:10.1038/343336a0 · Cited by 1,122
Bevilacqua, M. P., Pober, J. S., Wheeler, M. E., Cotran, R. S., & Gimbrone, M. A. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112200 · Cited by 1,104
Production of hybridoma growth factor by human monocytes
Aarden, L. A., De Groot, E. R., Schaap, O. L., & Lansdorp, P. M. (1987) · European Journal of Immunology · doi:10.1002/eji.1830171004 · Cited by 1,092
Eisenberg, S. P., Evans, R. J., Arend, W. P., Verderber, E., Brewer, M. T., Hannum, C. H., & Thompson, R. C. (1990) · Nature · doi:10.1038/343341a0 · Cited by 1,088
Matsushima, K., Morishita, K., Yoshimura, T., Lavu, S., Kobayashi, Y., Lew, W., Appella, E., Kung, H. F., Leonard, E. J., & Oppenheim, J. J. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.6.1883 · Cited by 1,021
Endothelial Cell Gene Expression of a Neutrophil Chemotactic Factor by TNF-α, LPS, and IL-1β
Strieter, R. M., Kunkel, S. L., Showell, H. J., Remick, D. G., Phan, S. H., Ward, P. A., & Marks, R. M. (1989) · Science · doi:10.1126/science.2648570 · Cited by 775
Kaye, J., Porcelli, S., Tite, J., Jones, B., & Janeway, C. A. (1983) · The Journal of experimental medicine · doi:10.1084/jem.158.3.836 · Cited by 640
Carter, D. B., Deibel, M. R., Dunn, C. J., Tomich, C.-S. C., Laborde, A. L., Slightom, J. L., Berger, A. E., Bienkowski, M. J., Sun, F. F., McEwan, R. N., et al. (1990) · Nature · doi:10.1038/344633a0 · Cited by 601
Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist.
Arend, W. P., Welgus, H. G., Thompson, R. C., & Eisenberg, S. P. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114622 · Cited by 581
Arfors, K., Lundberg, C., Lindbom, L., Lundberg, K., Beatty, P., & Harlan, J. (1987) · Blood · doi:10.1182/blood.v69.1.338.338 · Cited by 524
Cited by
A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes
Thornberry, N. A., Bull, H. G., Calaycay, J. R., Chapman, K. T., Howard, A. D., Kostura, M. J., Miller, D. K., Molineaux, S. M., Weidner, J. R., Aunins, J., et al. (1992) · Nature · doi:10.1038/356768a0 · Cited by 2,572
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Gérard, C., Bruyns, C., Marchant, A., Abramowicz, D., Vandenabeele, P., Delvaux, A., Fiers, W., Goldman, M., & Velu, T. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.2.547 · Cited by 796
Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro
Dinarello, C. A., & Thompson, R. C. (1991) · Immunology Today · doi:10.1016/0167-5699(91)90142-g · Cited by 724
Cytokines and the hepatic acute phase response
Moshage, H. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199703)181:3<257::aid-path756>3.0.co;2-u · Cited by 718
Glauser, M. P., Zanetti, G., Baumgartner, J.-D., & Cohen, J. (1991) · The Lancet · doi:10.1016/0140-6736(91)91452-z · Cited by 716
Interleukin-1 Receptor Antagonist
Arend, W. P. (1993) · Advances in Immunology · doi:10.1016/s0065-2776(08)60535-0 · Cited by 671
Inflammation in stroke and focal cerebral ischemia
Huang, J., Upadhyay, U. M., & Tamargo, R. J. (2006) · Surgical Neurology · doi:10.1016/j.surneu.2005.12.028 · Cited by 649
Cohen, S., Hurd, E., Cush, J., Schiff, M., Weinblatt, M. E., Moreland, L. W., Kremer, J., Bear, M. B., Rich, W. J., & McCabe, D. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10141 · Cited by 638
Interleukin 1 receptor antagonist. A new member of the interleukin 1 family.
Arend, W. P. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115453 · Cited by 595
Hypernociceptive role of cytokines and chemokines: Targets for analgesic drug development?
Verri, W. A., Cunha, T. M., Parada, C. A., Poole, S., Cunha, F. Q., & Ferreira, S. H. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.04.001 · Cited by 542
Alcami, A., & Smith, G. L. (1992) · Cell · doi:10.1016/0092-8674(92)90274-g · Cited by 482
Kinin receptors in pain and inflammation
Couture, R., Harrisson, M., Vianna, R. M., & Cloutier, F. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01318-8 · Cited by 472
Mathias, S., Younes, A., Kan, C.-C., Orlow, I., Joseph, C., & Kolesnick, R. N. (1993) · Science · doi:10.1126/science.8424175 · Cited by 433
Pereira, B. J. G., Shapiro, L., King, A. J., Falagas, M. E., Strom, J. A., & Dinarello, C. A. (1994) · Kidney International · doi:10.1038/ki.1994.117 · Cited by 384
Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1.
Kent, S., Bluthe, R. M., Dantzer, R., Hardwick, A. J., Kelley, K. W., Rothwell, N. J., & Vannice, J. L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9117 · Cited by 322
Influence of Interleukin‐1 Receptor Antagonist Gene Polymorphism on Disease
Witkin, S. S., Gerber, S., & Ledger, W. J. (2002) · Clinical Infectious Diseases · doi:10.1086/338261 · Cited by 301
Impaired Cytokine Signaling in Mice Lacking the IL-1 Receptor-Associated Kinase
Thomas, J. A., Allen, J. L., Tsen, M., Dubnicoff, T., Danao, J., Liao, X. C., Cao, Z., & Wasserman, S. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.2.978 · Cited by 280
Hack, C. E., Aarden, L. A., & Thus, L. G. (1997) · Advances in Immunology · doi:10.1016/s0065-2776(08)60597-0 · Cited by 280
Interleukin‐1 Signaling Is Essential for Host Defense during Murine Pulmonary Tuberculosis
Juffermans, N. P., Florquin, S., Camoglio, L., Verbon, A., Kolk, A. H., Speelman, P., van Deventer, S. J. H., & van der Poll, T. (2000) · The Journal of Infectious Diseases · doi:10.1086/315771 · Cited by 278
Perlstein, R. S., Whitnall, M. H., Abrams, J. S., Mougey, E. H., & Neta, R. (1993) · Endocrinology · doi:10.1210/en.132.3.946 · Cited by 257
Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6
Oldenburg, H. S. A., Rogy, M. A., Lazarus, D. D., van Zee, K. J., Keeler, B. P., Chizzonite, R. A., Lowry, S. F., & Moldawer, L. L. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230824 · Cited by 155
Self-citation
Metadata
- Authors
- McIntyre, K. W., Stepan, G. J., Kolinsky, K. D., Benjamin, W. R., Plocinski, J. M., Kaffka, K. L., Campen, C. A., Chizzonite, R. A., & Kilian, P. L.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1991-04-01
- Volume
- 173
- Issue
- 4
- Pages
- 931-939
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2035274613
- Cited by
- 289
- References
- 24
- FWCI
- 16.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.